Policy conditions make or break leaders in biopharmaceutical innovation: Preliminary results from the 2017 BCI Survey

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone ’s game. The 2017 results of the annualBiopharmaceutical Competitiveness& Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place. A number of BRICs and APAC countries punch below their weight in competitiveness because of detrimental policies for biopharmaceutical innovators. In contrast, the outstanding feature among those rated as most competitive in the 2017 BCI is a clear, systematic, and ongoing commitment to a policy environment that supports biopharmaceutical innovation. This is true for “newcomer” markets rated at the top – like Singapore, Israel, and Taiwan – as well as “mature” markets like Switzerland and the U.S.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Economic Impact Intellectual Property Policy Solutions Source Type: news